Hydrofarm restructures as revenue plunges 28%, cash falls to ~$11M and debt remains high

Snapshot
Hydrofarm Holdings Group, Inc. (NASDAQ: HYFM) - Q2 2025 10‑Q: the company is executing a second restructuring, shrinking product lines and footprint, managing debt and burning cash while revenue and margins remain pressured by industry oversupply.

Key facts & figures (reported)
* Net sales Q2 2025: $39,245 thousand (down 28.4% YoY from $54,793)
* Net sales H1 2025: $79,779 thousand (down 26.8% YoY from $108,965)
* Gross profit Q2 2025: $2,794 thousand (margin 7.1% vs 19.8% in Q2 2024)
* Net loss Q2 2025: $(16,861) thousand; basic EPS Q2 2025: $(3.63)
* Net loss H1 2025: $(31,246) thousand; basic EPS H1 2025: $(6.75)
* Cash & cash equivalents (6/30/2025): $10,991 thousand (down from $26,111 at 12/31/2024)
* Inventories (6/30/2025): $44,164 thousand (down from $50,633)
* Accounts receivable, net: $14,304 thousand (6/30/2025)
* Total assets: $389,875 thousand; Total liabilities: $194,866 thousand; Stockholders' equity: $195,009 thousand (6/30/2025)
* Term Loan principal: $114,452 thousand; Term‑Loan (net of discounts) reported ~ $111.6M; maturity Oct 25, 2028
* Revolving credit availability: ~ $9 million available to borrow (as of 6/30/2025)
* Shares outstanding (post 1‑for‑10 reverse split): 4,659,020 (as of Aug 4, 2025)

What's happening inside - operational items
* 2025 Restructuring Plan launched Q2 2025: estimated restructuring charges of $3,321 thousand recorded in Q2 (primarily inventory write‑downs). Company expects ~ $2 million more potential charges and annual run‑rate cost savings in excess of $3 million plus working capital benefits.
* Completed 2023 Restructuring and a 2024 IGE asset sale (sale proceeds and contract manufacturing agreement). Prior IGE sale generated an $11,520 thousand loss on asset disposition in 2024.
* Management continues to cut SG&A: SG&A down 13.5% in Q2 and 11.2% for H1 2025 vs prior year periods (driven by lower comp, facility costs and stock‑based comp reductions).
* Intangible amortization and depreciation remain material - amortization H1 2025: $11,864 thousand; D&A H1 2025: $14,721 thousand (total non‑cash charges significant).

Income statement - positives
* SG&A is falling: demonstrated cost savings from restructuring (SG&A H1 2025 $34.0M vs $38.3M prior year).
* Interest expense down modestly (Q2 2025 $3.4M vs $3.8M), reflecting some debt paydown and lower variable rates.
* Company remains in compliance with debt covenants as of 6/30/2025 and has undrawn revolver capacity (~$9M) - gives short‑term flexibility.

Income statement - negatives / risks
* Revenue collapse: -28.4% YoY in Q2; volume and mix declines (~27.9% reduction) driven by industry oversupply and weaker grower demand.
* Margin deterioration: gross margin fell from 19.8% (Q2 2024) to 7.1% (Q2 2025). Inventory markdowns and lower proportion of proprietary product sales hit gross profit hard; $3.3M of restructuring inventory markdowns impacted Q2 gross profit.
* Continued cash burn: operating cash used YTD $10.0M; cash balance fell by ~$15.1M in H1 2025 to $10.99M - runway dependent on working capital actions, asset sales or borrowing availability.
* Large intangible asset base & future amortization: intangible assets net $237,129 thousand (6/30/2025) with significant scheduled amortization (H2 and beyond), pressuring reported earnings.
* High leverage: Term Loan principal ~$114.5M (net long‑term debt ~ $111.6M) is material relative to equity; loan covenants and reinvestment/prepayment provisions (e.g., IGE proceeds reinvestment and the $4,544K prepayment in Q2) constrain flexibility.
* Market risk: company cites ongoing agricultural oversupply, trade/tariff risk, and slow cannabis regulatory reform as demand headwinds.

Near‑term catalysts / items to monitor
* Execution of 2025 restructuring - actual additional charges vs expected >$3M annual savings.
* Cash position and revolver availability - any draw or covenant changes.
* Sales recovery or further deterioration in core U.S. and Canadian markets (CEA/hydroponics demand).
* Any asset sales (land, brands) or further outsourcing/contract manufacturing that generate cash or reduce capex.
* Debt schedule and interest rate moves (Term Loan is variable; ~100 bps move ≈ $1.2M annual interest change per company sensitivity).

Bottom line (straightforward)
Hydrofarm (NASDAQ: HYFM) is shrinking to right‑size cost structure and working capital after a steep revenue and margin contraction driven by industry oversupply. Management is cutting SG&A and pursuing restructuring/asset actions, but the company still shows sizable losses, a depleted cash balance (~$11.0M), and material net debt (~$111-114M). The story now hinges on successful execution of the 2025 restructuring, cash generation from working‑capital reductions or asset sales, and stabilization of end‑market demand. Monitor cash, revolver availability, and any covenant developments closely.

If you want, I can produce a 1‑page quick chart of the income statement trends and a short scenario analysis for cash runway based on current burn and available liquidity.